Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Deutsche Bank Maintains Buy on DuPont de Nemours, Lowers Price Target to $60

Deutsche Bank analyst David Begleiter maintains DuPont de Nemours (NYSE:DD) with a Buy and lowers the price target from $70 to $60.
byBenzinga Newsdesk
October 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Deutsche Bank analyst David Begleiter maintains DuPont de Nemours (NYSE:DD) with a Buy and lowers the price target from $70 to $60.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Why Processa Pharmaceuticals Stock Is Soaring

By Erica Kollmann
January 25, 12:32 PM
Processa Pharmaceuticals shares are soaring Thursday after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. Processa said the data obtained from the Phase 1b trial has been used to select two dosage regimens for the Phase 2 trial which will be in advanced or metastatic breast cancer given the FDA's agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.

PCSA